Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AFMTE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU2023308528A1 ADC1
|
|||||
| Synonyms |
AU2023308528A1 ADC1
Click to Show/Hide
|
|||||
| Organization |
PHEON THERAPEUTICS LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
PBD aromatic-amide derivative
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
6-Maleimidocaproic acid
|
Linker Info | ||||
| Conjugate Type |
site 2-formylglycine (fGly)residue random conjugation
|
|||||
| Combination Type |
N- (4- ((S)-2- ((S)-2- (6- (2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3 methylbutanamido)propanamido)phenyl)-4- (4- (4- (4- (( (S)-2-methoxy-12-oxo 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-3-yl)oxy)butanamido)-1 methyl-1H-pyrrol-2-carboxamido)phenyl)-1-methyl-1H-pyrrol-2-carboxamide
|
|||||